INTRAHEPATIC CHOLANGIOCARCINOMA
Clinical trials for INTRAHEPATIC CHOLANGIOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new INTRAHEPATIC CHOLANGIOCARCINOMA trials appear
Sign up with your email to follow new studies for INTRAHEPATIC CHOLANGIOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug duo targets rare bile duct cancer in promising trial
Disease control OngoingThis study tests a combination of two drugs, atezolizumab and derazantinib, in 27 adults with advanced intrahepatic cholangiocarcinoma (a type of bile duct cancer) that has a specific FGFR2 gene change. The goal is to see if the treatment can shrink tumors and to check for side e…
Matched conditions: INTRAHEPATIC CHOLANGIOCARCINOMA
Phase: PHASE2 • Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest • Aim: Disease control
Last updated May 26, 2026 09:01 UTC
-
Immunotherapy duo takes on rare tumors in nationwide trial
Disease control OngoingThis study tests two immunotherapy drugs, nivolumab and ipilimumab, in adults with over 50 types of rare cancers. The goal is to see if this drug combination can shrink tumors or stop them from growing. The trial is no longer enrolling new participants, but results will help guid…
Matched conditions: INTRAHEPATIC CHOLANGIOCARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 08:59 UTC
-
New pump system targets liver tumors with direct chemo
Disease control OngoingThis study is testing a combined pump and catheter system that delivers chemotherapy directly to the liver in adults with colorectal cancer or bile duct cancer that has spread to the liver. The goal is to see if the system is safe and works properly. Participants will be monitore…
Matched conditions: INTRAHEPATIC CHOLANGIOCARCINOMA
Phase: NA • Sponsor: Ronald DeMatteo, M.D. • Aim: Disease control
Last updated May 26, 2026 08:56 UTC
-
New combo therapy targets hard-to-treat liver cancer
Disease control OngoingThis study tests whether adding immunotherapy drugs (durvalumab alone or with tremelimumab) to a type of internal radiation therapy (Y-90 SIRT) can shrink tumors in people with advanced bile duct cancer that has not spread beyond the liver. About 50 adults with this rare liver ca…
Matched conditions: INTRAHEPATIC CHOLANGIOCARCINOMA
Phase: PHASE2 • Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest • Aim: Disease control
Last updated May 22, 2026 14:02 UTC
-
New drug cocktail aims to stop bile duct cancer from coming back
Disease control OngoingThis study tests whether giving a combination of immunotherapy (Toripalimab), a targeted drug (Lenvatinib), and chemotherapy (GEMOX) before surgery can improve outcomes for people with a high-risk type of bile duct cancer. About 178 participants will be randomly assigned to recei…
Matched conditions: INTRAHEPATIC CHOLANGIOCARCINOMA
Phase: PHASE2, PHASE3 • Sponsor: Shanghai Zhongshan Hospital • Aim: Disease control
Last updated May 22, 2026 13:51 UTC
-
Liver tumor treatment study halted before start
Knowledge-focused TerminatedThis study aimed to review past patient records to understand how well radioembolization works for liver tumors, including intrahepatic cholangiocarcinoma and metastatic liver cancer. The goal was to learn about survival and tumor recurrence. However, the study was withdrawn befo…
Matched conditions: INTRAHEPATIC CHOLANGIOCARCINOMA
Sponsor: Methodist Health System • Aim: Knowledge-focused
Last updated May 20, 2026 11:56 UTC